Last reviewed · How we verify
amantadine sulfate
Amantadine blocks the M2 ion channel of influenza A virus, preventing viral uncoating and replication, and also increases dopamine release in the central nervous system.
Amantadine blocks the M2 ion channel of influenza A virus, preventing viral uncoating and replication, and also increases dopamine release in the central nervous system. Used for Influenza A prophylaxis and treatment, Parkinson's disease, Drug-induced extrapyramidal reactions.
At a glance
| Generic name | amantadine sulfate |
|---|---|
| Also known as | PK-merz, amantadine, physiological saline (0.9% NaCl solution), Osmolex ER Tablet, PKMERZ |
| Sponsor | Jee-Young Lee |
| Drug class | Antiviral / Dopamine agonist |
| Target | Influenza A M2 ion channel; dopamine system (mechanism not fully elucidated) |
| Modality | Small molecule |
| Therapeutic area | Virology; Neurology |
| Phase | FDA-approved |
Mechanism of action
As an antiviral, amantadine inhibits the M2 proton channel required for viral uncoating within host cells, thereby blocking influenza A virus replication. Additionally, amantadine has dopaminergic activity through unclear mechanisms, making it useful in treating Parkinson's disease and other movement disorders by enhancing dopamine availability in the brain.
Approved indications
- Influenza A prophylaxis and treatment
- Parkinson's disease
- Drug-induced extrapyramidal reactions
Common side effects
- Nervousness or anxiety
- Insomnia
- Dizziness
- Livedo reticularis
- Orthostatic hypotension
- Nausea
Key clinical trials
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection
- Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain (PHASE2)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (PHASE2, PHASE3)
- Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD) (EARLY_PHASE1)
- Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions (PHASE3)
- Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amantadine sulfate CI brief — competitive landscape report
- amantadine sulfate updates RSS · CI watch RSS
- Jee-Young Lee portfolio CI